Adicet Bio, Inc.

Item 5. Other Information.

(a)

Departure of Chief Medical Officer

On August 3, 2026, Julie Maltzman, M.D. notified Adicet Bio, Inc. (the “Company”) of her resignation as Chief Medical Officer of the Company, effective August 14, 2026 (the “Effective Date”). Dr. Maltzman’s resignation was not the result of any disagreement with the Company or its Board of Directors or any matter relating to the Company’s operations, policies, or practices. The Company has commenced a search for a new Chief Medical Officer.

Appointment of Interim Chief Medical Officer

Dr. Lloyd Klickstein, M.D., Ph.D. has been appointed as the Company’s Interim Chief Medical Officer, effective August 3, 2026.

Dr. Klickstein, age 69, has served as a member of our board of directors since August 2024. Dr. Klickstein has served as president and chief executive officer of Koslapp Therapeutics, Inc. since April 2024. From February 2021 to March 2024, Dr. Klickstein served as the founding chief executive officer and subsequently as president and chief scientific officer of Versanis Bio, Inc., a biopharmaceutical company that addressed medical conditions prevalent in older adults. Previously, Dr. Klickstein served as chief innovation officer of Adicet Bio from September 2020 to February 2021 and as chief scientific officer of resTORbio from May 2018 to September 2020. Prior to joining resTORbio, Dr. Klickstein was Head of Translational Medicine for the New Indication Discovery Unit (NIDU) and the Exploratory Disease Area (DAx) at Novartis Institutes for Biomedical Research. Dr. Klickstein received his B.S. degree from Tufts University, his M.D. and Ph.D. degrees from Harvard University, completed post-graduate clinical training in Internal Medicine, Rheumatology & Immunology at BWH and a post-doctoral research fellowship at the Center for Blood Research in Boston.

Dr. Klickstein and the Company have entered into a Consulting Agreement, dated August 5, 2026 (the “Consulting Agreement”), effective as of August 3, 2026, pursuant to which Dr. Klickstein has agreed to serve as interim Chief Medical Officer on a full-time basis during the term of the Consulting Agreement. As compensation for his services under the Consulting Agreement, Dr. Klickstein shall be paid $42,500 per month, is eligible for an additional cash incentive payment equal to forty (40) percent of the fees paid under the Agreement, and was granted an option to purchase 18,300 shares of the Company’s common stock at a per share exercise price based on the closing price of the Company’s common stock on The Nasdaq Capital Market as of August 5, 2026.

There are no other arrangements or understandings between Dr. Klickstein and any other persons pursuant to which Dr. Klickstein was appointed as interim Chief Medical Officer of the Company. There is no family relationship between Dr. Klickstein and any director or executive officer of the Company. There are no transactions between Dr. Klickstein and the Company that would be required to be reported under Item 404(a) of Regulation S-K.

The foregoing description of the Consulting Agreement does not purport to be complete and is subject to, and qualified in its entirety by, the final Consulting Agreement.

(c) None of our directors or “officers,” as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934, adopted orterminated a Rule 10b5-1 trading plan or arrangement or a non-Rule 10b5-1 trading plan or arrangement, as defined in Item 408(c) of Regulation S-K, during the fiscal quarter covered by this report.